Most viewed in the last 7 days from JAMA Oncology: Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. ja.ma/4bvJPDQ

Breaking the mold: Unconventional T cells in cancer therapy dlvr.it/TJRYrN

EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models dlvr.it/TJSx1B

"CDK4 selective inhibition improves preclinical antitumor efficacy and safety" cell.com/cancer-cell/fu… Pfizer Inc. Lars Anders Cancer Cell

Online now: Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity dlvr.it/TJsXmw

New evidence today NEJM that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…

Check out the new paper by HS Lee, Bryan M. Burt, Shanda Blackmon, MD, MPH et al about a prognosticator in pleural #mesothelioma. BCM_Surgery BCMHouston

For readers interested in approaches to reset the immune system to treat autoimmune diseases, here's a comprehensive review nature.com/articles/s4157… rdcu.be/elE4L

The innate power of NK cells in cancer therapy MalmbergLab Nature Medicine on Katy Rezvani, M.D., Ph.D trial nature.com/articles/s4159…

TNM classification 9ᵗʰ edition T stage radiologyassistant.nl/chest/lung-can…

A #TopRead article from Dr. Jesse Bruijnesteijn found that a diverse repertoire of killer cell immunoglobulin-like receptors (KIRs) contributes to the protection of individuals and populations against pathogen evasion and subversion. Read it in The JI: ow.ly/vJRk50VJI7H

This week we launched our “How To Workshop Series” with a session on understanding the grant review process, crafting specific aims, and developing a competitive research plan. Featuring: Livia Eberlin, Ravi Ghanta, Thomas Milner, Tamer Mohamed, Hyun-Sung Lee, R. Taylor Ripley,

Today, we honor the enduring legacy of Dr. Michael E. DeBakey, a visionary surgeon, educator and medical pioneer whose groundbreaking work transformed cardiovascular surgery. Dr. DeBakey died on this day in 2008 at the age of 99, leaving behind a legacy that continues to shape

🗨️ “Vaccines have done more to improve public health than any other medical intervention.” A Viewpoint focuses on cancer vaccines and the future of immunotherapy—analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve

Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma aacrjournals.org/clincancerres/…. Clinical Cancer Research, BCM Systems Onco-Immunology Laboratory, BCM_Surgery, BCMHouston. #mesothelioma #Immunotherapy

New #JITC review: Tumor organoids in immunotherapy: from disease modeling to translational research bit.ly/40ZwMGH

🫁 Tumour–microenvironment crosstalk in #NSCLC drives resistance, metastasis, and outcomes. Understanding spatial niches, inflammation, and immune evasion can reshape treatment strategies. 📖 NatureRevClinOncol 👉 doi.org/10.1038/s41571… #CánCare #immunotherapy #biomarkers

This #BriefReview focuses on interferon (IFN) production in the thymus and its effects on thymic antigen presenting cells and developing thymocytes examining the importance of T-cell tolerance to IFN and interferon-stimulated proteins. Read more: ow.ly/53zc50WuPIL.

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer dlvr.it/TMVKGH

And improvements for personalized cancer vaccines with stronger CD4+ and CD8+ responses. cell.com/cell/fulltext/…